RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology
985
because it possessed lipophilic characteristics, was fairly sol- formation by organisms causing haemodialysis catheter-related infec-
tions. J Antimicrob Chemother 62:1024–1026.
uble in 30% ethanol/pH 7.4 buffer, underwent rapid hydrolysis
to produce the parent drug and improved the in vitro skin deliv-
ery of ketorolac. The good penetration detected for KT is likely
the result of a refined balance between lipophilicity and solubil-
ity in 30% ethanol/pH 7.4 buffer. Although the more lipophilic
prodrugs such as KH and DKH exhibited a lower flux than did
KT or KB, they appeared to be more suitable for sustained and
prolonged delivery. According to the experimental data, we can
suggest a criterion for designing an ideal prodrug for percuta-
14. Davison Z, Nicholson RI, Maillard JY, Denyer SP, Heard CM. 2009.
Control of microbial contamination of Franz diffusion cell receptor
phase in the development of transcutaneous breast cancer therapeu-
tics. Lett Appl Microbiol 49:456–460.
15. Teichmann A, Jacobi U, Ossadnik M, Richter H, Koch S, Sterry W,
Lademann J. 2005. Differential stripping: Determination of the amount
of topically applied substances penetrated into the hair follicles. J In-
vest Dermatol 125:264–269.
16. Zhang LW, Al-Suwayeh SA, Hsieh PW, Fang JY. 2010. A compar-
neous penetration. The optimal promoiety is a short alkyl chain ison of skin delivery of ferulic acid and its derivatives: Evaluation of
their efficacy and safety. Int J Pharm 399:44–51.
with moderate solubility. A branched chain moiety is passable
in the cases of short alkyl chains, although the bulkier moi-
ety may retard passage across the SC. Aromatic promoieties
are more acceptable than long alkyl chains. All prodrugs ef-
fectively demonstrated an acceptable level of alteration of skin
structure and morphology. These findings indicate that ester
prodrugs are a feasible approach for improving the analgesic
therapy of ketorolac.
17. Chiu TM, Huang CC, Lin TJ, Fang JY, Wu NL, Hung CF. 2009. In
vitro and in vivo anti-photoaging effects of an isoflavone extract from
soybean cake. J Ethnopharmacol 126:108–113.
18. Higuchi T. 1960. Physical chemical analysis of percutaneous absorp-
tion process from creams and ointments. J Soc Cosmet Chem 11:85–97.
19. Vaddi HK, Hamad MO, Chen J, Banks SL, Crooks PA, Stinch-
comb AL. 2005. Human skin permeation of branched-chain 3-O-
alkyl ester and carbonate prodrugs of naltrexone. Pharm Res 22:758–
765.
20. Tzeng JI, Su WL, Chu KS, Cheng KI, Chu CC, Shieh JP, Wang JJ.
2005. Pharmacokinetics of ketorolac pentyl ester, a novel ester deriva-
tive of ketorolac, in rabbits. Kaohsiung J Med Sci 21:365–370.
21. Ackaert OW, De Graan J, Capancioni R, Della Pasqua OE, Dijk-
stra D, Westerink BH, Danhof M, Bouwstra JA. 2010. The in vitro
and in vivo evaluation of new synthesized prodrugs of 5-OH-DPAT for
iontophoretic delivery. J Control Release 144:296–305.
ACKNOWLEDGMENT
The authors are grateful to the financial support from Chang
Gung Memorial Hospital (grant number: CMRPD190353).
22. Yamashita N, Tachibana K, Ogawa K, Tsujita N, Tomita A. 1997.
Scanning electron microscopic evaluation of the skin surface after ul-
trasound exposure. Anat Rec 247:455–461.
23. Hsieh PW, Al-Suwayeh SA, Fang CL, Lin CF, Chen CC, Fang JY.
2012. The co-drug of conjugated hydroquinone and azelaic acid to en-
hance topical skin targeting and decrease penetration through the skin.
Eur J Pharm Biopharm 81:369–378.
24. De Rosa FS, Tedesco AC, Lopez RFV, Pierre MBR, Lange N,
Marchetti JM, Rotta JCG, Bentley MVLB. 2003. In vitro skin per-
meation and retention of 5-aminolevulinic acid ester derivatives for
photodynamic therapy. J Control Release 89:261–269.
25. Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. 2009. Skin perme-
ation of buprenorphine and its ester prodrugs from lipid nanoparticles:
Lipid emulsion, nanostructured lipid carriers, and solid lipid nanopar-
ticles. J Microencapsul 26:734–747.
26. Morrow DIJ, McCarron PA, Woolfson AD, Juzenas P, Juzeniene A,
Iani V, Moan J, Donnelly RF. 2010. Hexyl aminolevulinate is a more ef-
fective topical photosensitiser precursor than methyl aminolevulinate
and 5-aminolevulinic acids when applied in equimolar doses. J Pharm
Sci 99:3486–3498.
27. Rautio J, Nevalainen T, Taipale H, Vepsa¨la¨inen J, Gynther J, Laine
K, Ja¨rvinen T. 2000. Piperazinylalkyl prodrugs of naproxen improve in
vitro skin permeation. Eur J Pharm Sci 11:157–163.
28. Kim MK, Lee CH, Kim DD. 2000. Rat skin permeation of testos-
terone and its ester derivatives. J Pharm Pharmacol 52:369–375.
29. Yan YD, Sung JH, Lee DW, Kim JS, Jeon EM, Kim DD, Kim DW,
Kim JO, Piao MG, Li DX, Yong CS, Choi HG. 2011. Evaluation of
physicochemical properties, skin permeation and accumulation pro-
files of salicylic acid amide prodrugs as sunscreen agent. Int J Pharm
419:154–160.
REFERENCES
1. Lee WR, Shen SC, Al-Suwayeh SA, Yang HH, Li YC, Fang JY.
2013. Skin permeation of small-molecule drugs, macromolecules, and
nanoparticles mediated by a fractional carbon dioxide laser: The role
of hair follicles. Pharm Res 30:792–802.
2. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Ja¨rvinen
T, Savolainen J. 2008. Prodrugs: Design and clinical applications. Nat
Rev Drug Discov 7:255–270.
3. Majumdar S, Sloan KB. 2007. Topical delivery of N-alkyl-N-
alkylcarbonylaminomethyl (NANAOCAM) prodrugs of theophylline
(ThH). Int J Pharm 332:64–71.
4. Liu SY, Shieh JP, Tzeng JI, Hou CH, Cheng YL, Huang KL, Wang JJ.
2005. Novel depots of ketorolac esters have long-acting antinociceptive
and antiinflammatory effects. Anesth Analg 101:785–792.
5. Amrish C, Kumar SP. 2009. Transdermal delivery of ketorolac. Yaku-
gaku Zasshi 129:373–379.
6. Halen PK, Murumkar PR, Giridhar R, Yadav MR. 2009. Prodrug
designing of NSAIDs. Mini-Rev Med Chem 9:124–139.
7. Mishra A, Veerasamy R, Jain PK, Dixit VK, Agrawal RK. 2008. Syn-
thesis, characterization and pharmacological evaluation of amide pro-
drugs of ketorolac. Eur J Med Chem 43:2464–2472.
8. Doh HJ, Cho WJ, Yong CS, Choi HG, Kim JS, Lee CH, Kim DD. 2003.
Synthesis and evaluation of ketorolac ester prodrugs for transdermal
delivery. J Pharm Sci 92:1008–1017.
9. Puglia C, Filosa R, Peduto A, de Caprariis P, Rizza L, Bonina F,
Blasi P. 2006. Evaluation of alternative strategies to optimize ketorolac
transdermal delivery. AAPS PharmSciTech 7:64.
10. Qandil A, Al-Nabulsi S, Al-Taani B, Tashtoush B. 2008. Synthesis
of piperazinylalkyl ester prodrugs of ketorolac and their in vitro evalu-
ation for transdermal delivery. Drug Dev Ind Pharm 34:1054–1063.
11. Liu KS, Sung KC, Al-Suwayeh SA, Ku MC, Chu CC, Wang JJ, Fang
JY. 2011. Enhancement of transdermal apomorphine delivery with a
diester prodrug strategy. Eur J Pharm Biopharm 78:422–431.
12. Campbell CSJ, Contreras-Rojas LR, Delgado-Charro MB, Guy RH.
2012. Objective assessment of nanoparticle disposition in mammalian
skin after topical exposure. J Control Release 162:201–207.
13. Takla TA, Zelenitsky SA, Vercaigne LM. 2008. Effectiveness of a
30% ethanol/4% trisodium citrate locking solution in preventing biofilm
30. Sloan KB, Wasdo S. 2003. Designing for topical delivery: Prodrugs
can make the difference. Med Res Rev 23, 763–793.
31. Montenegro L, Carbone C, Maniscalco C, Lambusta D, Nicolosi G,
Ventura CA, Puglisi G. 2007. In vitro evaluation of quercetin-3-O-acyl
esters as topical prodrugs. Int J Pharm 336:257–262.
32. Lin CH, Fang CL, Al-Suwayeh SA, Yang SY, Fang JY. 2011. In
vitro and in vivo percutaneous absorption of seleno-L-methionine, an
antioxidant agent, and other selenium species. Acta Pharmacol Sin
32:1181–1190.
DOI 10.1002/jps.23888
Liu et al., JOURNAL OF PHARMACEUTICAL SCIENCES 103:974–986, 2014